Eidos Therapeutics, Inc. (EIDX): Price and Financial Metrics
EIDX Price/Volume Stats
| Current price | $122.21 | 52-week high | $132.54 |
| Prev. close | $128.44 | 52-week low | $28.39 |
| Day low | $116.83 | Volume | 335,500 |
| Day high | $128.49 | Avg. volume | 128,113 |
| 50-day MA | $108.40 | Dividend yield | N/A |
| 200-day MA | $65.26 | Market Cap | 4.75B |
EIDX Stock Price Chart Interactive Chart >
Eidos Therapeutics, Inc. (EIDX) Company Bio
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
Latest EIDX News From Around the Web
Below are the latest news stories about Eidos Therapeutics Inc that investors may wish to consider to help them evaluate EIDX as an investment opportunity.
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for MergerPALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021. The closing of the transaction is subject to the receipt of approvals from BridgeBio and Eidos stockholders at special meetings of each company’s stockholders, both of which are scheduled for January 19, 2021, and the satisfaction or waiver of other conditions to closing. Leading proxy advisory firms Institutional Shareholder Services and Glass Lewis recommend ... |
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerNEW YORK, NY / ACCESSWIRE / January 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * PNM Resources, Inc. (NYSE:PNM) relating to its proposed acquisition by Avangrid, Inc. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, IPHI, ALXN, and XLNX Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed MergerPALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional… |
EIDX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 168.42% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 129.27% |
| 2019 | 317.08% |
Loading social stream, please wait...